GENOCEA BIOSCIENCES INC by Genocea Biosciences, Inc. (GNCAQ)

About GENOCEA BIOSCIENCES INC by Genocea Biosciences, Inc. (GNCAQ)

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

GENOCEA BIOSCIENCES INC by Genocea Biosciences, Inc. News